Having more than a decade of experience conducting users research on eClinical platforms under their collective belt, the analysts with Life Science Strategy Group (LSSG) have observed dynamic, interesting shifts in the industry. Customers have migrated from one provider to another, and clear leaders have emerged among the vendors.
With “Strategic Analysis of the eClinical Platform Market and Competitive Landscape: A Market Undergoing Perceptual Change,” LSSG offers a glimpse into users’ feelings about the platforms they currently use, and perceptions of the other companies offering eClinical solutions. According to LSSG, the report’s findings indicates pharmaceutical companies are on the hunt for eClinical platforms that guarantee data quality and integrity, while also improving overall efficiency.
Jon Meyer, LSSG co-founder and principal, told Outsourcing-Pharma that the team “put a lot of analysis and thought into this report,” which offers a great deal of insight.
“The survey and report reveals who is making purchase decisions, what the awareness of providers is in the market place (aided and unaided), to customers value most in an eClinical platform [page 23], what is considered a key platform component, how satisfied is the market with the various platforms, how often people switch platforms and why, who they switch to, and also how the leading eClincal platforms compare across a series of performance criteria,” he explained.
Additionally, Meyer said, the findings could be useful for eClinical tech providers in determining exactly what users are looking for in a solution.
“The takeaways are that customers want to use an eClinical platform to increase productivity and to give a consistent experience across their daily workflows,” he told OSP. “When selecting an eClinical platform, the data always comes first (data integrity, security and reliability), but real time access, ease of use and integration of the platform with internal systems is also very important; this especially important as more trials incorporate bolt on technologies to support decentralization.”
The report also shows who the perceived market leaders are, but that the current top players might want to keep an eye on the up-and-comers.
“The current market leader, Medidata, has its work cut out for it as Veeva is really outperforming it across the majority of the metrics we looked at,” he related. “Also, while not pure tech platform companies, IQVIA and Covance also performed quite well.”
The eClinical report shares comprehensive breakdowns in a number of areas, including:
How satisfied are users with their current eClinical platforms?
- Extremely satisfied: 10%
- Mostly satisfied: 23%
- Somewhat satisfied: 47%
- Neither satisfied nor dissatisfied: 17%
- Somewhat dissatisfied: 1%
- Mostly dissatisfied: 1%
- Not at all satisfied: 1%
The report asked the 13 out of 16 respondents who anticipated switching which platforms they were eyeballing; here were the top three answers:
- IQVIA Infosario: 7
- Veeva Vault Clinical: 4
- Oracle Platform and Clinical One: 3
What were the top benefits and value propositions in the eyes of respondents? Here are the 5 top features and percent of respondents listing them as important:
- Increasing user productivity: 53%
- Providing a consistent user experience with cross-product workflows: 47%
- Earlier trial initiation and faster patient enrollment: 44%
- Streamlining issue and question resolution: 39%
- Reducing long-term cost: 35%
Then, the survey asked top rationales for switching platforms—the two most frequently listed reasons were:
- The other eClinical platform offered better capabilities/performance: 52%
- There were technical issues with the eClinical platform
For more information or to download the report, visit LifeScienceStrategy.com.